We have examined a population of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) for loss of heterozygosity of polymorphic markers on chromosomes 5 and 7. The rationale for this study was the observation that the majority of patients with therapy-related leukemia (t-AML or t-MDS), resulting from cytotoxic treatment for prior malignancies, have loss of chromosome 5 and/or 7 or deletions involving the long arms of one or both of these chromosomes. This cytogenetic finding suggested that tumorsuppressor genes, important in the development of AML, may be located in these chromosomal regions. We analyzed a total of 60 patients, 43 with primary MDS/AML de novo and 17 with t-MDS/t-AML. Leukemia cells were evaluated HERAPY-RELATED malignant myeloid disorders de-
T velop in a proportion of patients who have received chemotherapy and/or radiotherapy for other primary malignancies. ' The risk has been estimated at 3% to 7% at 10 years after treatment for Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma, depending on the type (eg, chemotherapy, radiotherapy, or both) and amount of treatment and the age of the patient? Clonal chromosome abnormalities are found in the bone marrow cells of the vast majority of patients with therapy-related acute myeloid leukemia (t-AML) or myelodysplastic syndrome (t-MDS). Up to 80% of the patients with these diseases have loss of material from chromosomes 5 and/or 7, with either loss of an entire chromosome (-5 or -7), an interstitial deletion of the long arm [del(5q) or del(7q)], or an unbalanced translocationgs4 (LeBeau MM, Rowley JD, Larson RA, et al, unpublished data). This karyotypic pattern is quite different from that found in most patients with primary MDS or AML de novo; other abnormalities, including specific translocations, are characteristic of different subtypes with distinctive morphologies. A small proportion of patients with primary MDS/AML de novo do have loss of material from chromosomes 5 and/or 7; approximately 39% of the individuals with these abnormalities have had documented occupational exposure to possibly mutagenic agents?7
Tumor-suppressor genes have been implicated in the development of several types of solid tum0rs.8,~ Those that have been identified so far include the retinoblastoma (RBI) gene,"." DCC ("deleted in colorectal car~inoma")'~ and MCC ("mutated in colorectal ~arcinoma"),'~ W T I , which is involved in the development of Wilms' and TP53, which is altered in many types of tum01-s.'~ The first step in the localization of the RBl and Wilms' tumor genes was the identification of recurring deletions of specific chromosome Based on this information, investigators discovered loss of heterozygosity at polymorphic loci in these same regions in patients without cytogenetic deletions?' The rationale for this approach was the hypothesis that expression of recessive mutations in a gene critical to the development of cancer could result from genetic events leading to homozygosity or hemizygosity of a single mutant allele; some of these events, including chrofor restriction fragment length polymorphisms (RFLPs). Leukemia cell genotypes were compared with lymphoblastoid cell genotypes from the same patients. Two cases of loss of heterozygosity were identified from chromosomes lacking visible deletions: one involving chromosome 5 in a patient with AML de novo who had a visible deletion of 5q at a later stage of the disease, and one involving chromosome 7 in a patient with t-AML. We conclude that allele loss from loci on chromosomes 5 and 7 in MDS/AML, when it occurs, usually results from major deletion or simple chromosome loss, rather than from mitotic recombination or chromosome loss with duplication of the remaining homologue.
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mosome loss and mitotic recombination, would also lead to loss of heterozygosity of other markers on the same chromosome?' These same strategies currently are being applied to studies of other types of solid tumors, such as small cell carcinoma of the lung22 and neurobla~toma,2~ which are associated with deletions of the short arms of chromosomes 3 and 1, respectively.
There are fewer data implicating tumor-suppressor genes in the development of leukemia. The TP53 gene on 17p has been found to be rearranged in leukemia cells from a significant fraction of chronic myeloid leukemia (CML) patients, predominantly in blast crisis?e26 Recently, rearrangements of the R B I gene have been reported in two patients with MDSZ7 and in four patients with lymphoid malignancies? 8 The observation that deletions of chromosomes 5 and 7 are frequent in t-AML/t-MDS suggests that there may be tumor-suppressor genes involved in the development of this leukemia. By cytogenetic analysis of patients with a del(5q) (105 patients), we previously identified a region of 5q, 
MATERIALS AND METHODS
The patients included in this study were evaluated at the University of Chicago Medical Center and were each assigned a unique patient number? The diagnosis of t-MDS, t-AML, primary MDS, or AML de novo was made by morphologic study of bone marrow specimens and peripheral blood. Each patient with t-MDS or t-AML had received cytotoxic therapy (chemotherapy, radiotherapy, or both) for an antecedent disease. The diagnosis of t-MDS was made when the patient's peripheral blood and bone marrow showed features of dyspoiesis as defined by the French-American-British (FAB) criteria for MDS and described by us and others as characteristic of the changes in t-MDS."'" Patients classified as having t-MDS had less than 30% blasts in the marrow, whereas the diagnosis of overt t-AML was made when the percentage of blasts was greater than 30%, as determined from marrow aspirates or as judged from marrow biopsy sections when increased reticulin prevented aspiration. Clinical data were collected, and details concerning the primary treatment were obtained from a review of each patient's medical history. Radiation therapy ports, the dose of each treatment course in cGy, and the doses and duration of each chemotherapy course were determined whenever possible for each patient.
The diagnosis of primary MDS or AML de novo was made according to the FAB riter ria.""^ None of these patients had received cytotoxic treatment for a previous disorder, and none had developed leukemia as a terminal phase of a chronic myeloproliferative disorder. All samples were obtained with informed consent, according to the guidelines approved by the Institutional Review Board of the University of Chicago.
Cytogenetic analyses of bone marrow cells or peripheral blood cells were performed as previously described. ' Mononuclear cells were separated from peripheral blood by density centrifugation over Ficoll-Hypaque by the method of B~yum.'~ Epstein-Barr virus (EBV) was harvested from the marmoset lymphoblastoid cell line B95-8. Supernatant from cultures at a cell density of approximately 106/mL was filtered twice through a 0.45-km HA Millipore (Bedford, MA) filter. Mononuclear cells (2 x lo6) were suspended in 2 mL of filtrate in a 15-mL conical tube (without cyclosporine) and incubated at 37°C. After 2 days, the EBV-containing culture medium was removed, and cells were resuspended in 5 mL complete medium (RPMI 1640 supplemented with 10% fetal calf serum, antibiotics, and 4 mmol/L L-glutamine) in T-25 flasks. Characteristic clusters of transformed cells were visible 10 to 60 days later.
Clinical and morphological analysis.
Cytogenetics.
Epstein-Barr virus transformation of B lymphocytes.
Southem 6lotting. Leukemia cell samples used in this study consisted of mononuclear fractions from Ficoll-Hypaque gradients of bone marrow or peripheral blood samples that contained at least 70% malignant cells. High-molecular weight DNA was isolated from leukemia cells and lymphoblastoid lines by phenol extraction and ethanol precipitation. DNA was digested with restriction enzymes according to instructions from the manufacturer (New England Biolabs, Bedford, MA), using a 7.5-fold excess of enzyme. Blotting and hybridization were performed as previously described? except that in some cases yeast RNA (500 kg/mL) was substituted for salmon sperm DNA and DNA was bound to filters by treatment with UV irradiation?' rather than by baking.
Whenever possible, the polymorphism analysis was performed using DNA from the same leukemia cell sample that was analyzed cytogenetically. Of 12 exceptions, four were cases in which the sample available for DNA isolation was obtained during progression of the leukemia, between the dates of two other samples that were karyotyped and had nearly identical cytogenetic profiles. In eight cases, the sample available for DNA isolation was obtained after the last sample that was analyzed cytogenetically; in each of these individuals, the disease had continued to progress up to the time that the sample used for DNA extraction was obtained.
The probes used on Southern blots were: chromosome Probes.
CRI-L1265 (D5S52), pJ0205E-C and pJ0205H-C (D5S22), and hMS8 (D5S43); chromosome 7, pJ5.11 (D7S10), TM102L (D7S135), pRMU7.4 (D7S370), NJ-1 and NJ-3 (COLIAZ), pJ3.11 (D7S8), pmetH and pmetD (MET), pB79a (D7S13), 7C22 (D7S18), pXV-2c (D7S23), CRI-(D7S371), pYNB3.1R (D7S372) and hg3 (D7S22); and, chromosome 2, pYNH24 (D2S44). 38 KM-19 and CS.7 (D7S23) and (1) for KM-19, denaturation time was 2 minutes and extension time was 3 minutes (10 minutes for the final extension), and (2) the primers used for CS.7
were 5'-GGGAGAGAAGCGAAGCAATG-3' and 5'-GGTITTA-GACACGGGTGCATGA-3'. KM-19 and CS.7 products were treated with restriction enzymes (PstI or HhaI, respectively) before electrophoresis. Amplification products were visualized on ethidium-bromide-stained 2% agarose gels.
S194 (D7S104), JURP-2 (TCRB), TCRG cDNA, pTHH28
Polymerase chain reactions. In addition, all samples were assayed for genotypes at the highly polymorphic D2S44 and/or APOB loci, both of which are located on chromosome 2, in order to verify that pairs of DNA samples from leukemia cells and lymphoblastoid lines were actually derived from the same patient. This precaution was taken since the EBV-transformation process is several weeks in duration, allowing opportunities for sample mix-ups or cell-line cross-contamination.
RESULTS

Electrophoretic
Chromosome 5 and 7 RFLP data on these patients are shown in Table 1 . Data on patients without visible abnormalities of chromosomes 5 and 7 were included in Table 1 only if at least one marker on each chromosome was informative (ie, lymphoblastoid cells were heterozygous); data on patients with a deletion of chromosome 5 were included if at least one marker on chromosome 7 was. informative, and vice versa. When possible, markers within cytogenetically detectable deletions were assayed as well. (In therapy-related cases, it was often possible to obtain only a limited amount of DNA, since the bone marrow in these patients is frequently hypocellular or fibrotic and, therefore, difficult to aspirate.) Samples were obtained either at diagnosis or from patients with residual disease.
Patients classified as having an abnormality of chromosome 5 or 7 all had the abnormality present in the majority of the leukemia cells at the stage of the disease when DNA was extracted, with the exception of the one patient (2087) indicated in Table 1 , who had the abnormality in only 35% of cells karyotyped. In those cases where translocations are specified, they were unbalanced with loss of material distal to the breakpoint on chromosome 5 or 7. Many of the patients had abnormalities of other chromosomes, which are not delineated here. A summary of the data on patients with t-MDS/t-AML is given in Table 2 . The two patients designated "atypical" had been treated for prior malignancies, but in both cases the leukemia clinically resembled AML de novo.
All of the losses of heterozygosity observed reflected abnormalities that were detected cytogenetically, with one exception (patient 2092). This patient was studied at three different times, as indicated in Table 1 . She presented with t-AML at the time of the first sample, having been previously treated successfully with chemotherapy for breast cancer. Throughout the remainder of her life there was no further evidence of breast cancer. She was subsequently treated for the leukemia and experienced a brief remission; she then relapsed with an MDS, which after 8 months progressed again to overt t-AML. The second sample was obtained during this transition period from t-MDS to t-MDS/t-AML patients.
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t-AML and the third after progression to t-AML. Cytogenetic analysis was performed on both the first and third samples; although clonal abnormalities were detected, they did not involve chromosomes 5 or 7. Figure 2 shows the Southern blots of the markers for which loss of heterozygosity occurred in patient 2092, along with some examples from patients in whom there was no loss of heterozygosity observed for the same markers. Allele loss was observed in all three leukemia samples at D7S23 (in the CF region), TCRB, D7S372, and D7S22; whether this resulted from mitotic recombination or chromosome loss and duplication could not be determined, since the lymphoblastoid cell genotype was not informative for additional markers on chromosome 7, including D7S371 and COLIA2, located proximal to the CF region on 7q, and D7S10, D7S135, D7S370, and TCRG on 7p.
We previously reported a patieht (2095) with t-AML whose cells showed loss of heterozygosity for several 7q markers, including loci in the CF region, D7S372, and D7S22, with an increase in the proportion of cells with allele loss as the leukemia pr~gressed.~' Although the patient's bone marrow showed no aberrations of chromosome 7 at the time of diagnosis (March 1987, 93 cells examined), cytogenetic analysis of serial samples showed the evolution of an unbalanced 7;13 translocation, which resulted in loss of 7q distal to q11.2 [-7,+der(7)t(7; 13)(qll.%q14)]. Thirty percent of metaphase cells analyzed 9/87 were -7,+der(7), whereas 91% of cells analyzed 6/88 had the der(7). Loss of heterozygosity was detectable only at CF loci (D7S8 [data not shown] and D7S23) in the earliest sample from which DNA was extracted (October 1987), but was clearly evident at all informative chromosome 7 loci in a sample obtained in January 1988, and appeared to be complete in a sample obtained in May 1988. Thus, the proportion of cells showing loss of heterozygosity by RFLP analysis and the translocation by cytogenetic analysis was similar at various stages and increased with time. Autoradiographs of Southern blots on markers for which allele loss was observed in this patient are shown in Fig 3. These results demonstrate that it is important to perform parallel cytogenetic and molecular analyses to establish mechanisms of loss of heterozygosity.
RFLP data on these patients are given in Table 3 (patients without visible abnormalities of chromosomes 5 or 7, arranged according to FAB subtype) and Table 4 (patients with visible abnormalities of chromosome 5 or 7); these data are summarized in Table 2 . In addition to the data shown in Table 2 , there were two patients informative only for markers on chromo-
Primaly MDSIAML de novo patients.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From some 5 and 14 patients informative only for markers on chromosome 7 who did not have karyotypic abnormalities of these chromosomes; loss of heterozygosity was not observed in any of those individuals. Among the patients for whom data are shown in Table 2 , the only one lacking cytogenetic deletions in whom loss of heterozygosity was observed was patient 196. The leukemia cells from this patient that were available for DNA isolation were from a sample that had been stored frozen at the time of diagnosis in 1983. Abnormalities of chromosomes 5 and 7 were not detected cytogenetically at that time, but we observed a reduced intensity of one of the allelic bands at the D5S70 locus, as shown in Fig 4. The patient had a complete remission after treatment and relapsed in 1986; at this time a de1(5)(q32q35) was detected in 41% of the cells examined. It may be that this deletion was present in a significant fraction of slowly cycling cells even at the time of diagnosis and was detected by the RFLP probe. This finding indicates that the use of appropriate DNA probes may be of diagnostic value in some cases of AML. As indicated in Tables 1 and 4 , there were 15 patients (six patients with primary MDS/AML de novo and nine with t-MDS/t-AML) with deletion or loss of chromosomes 5 and/or 7 for whom markers in the deleted regions were informative. Allele loss was detected by RFLP analysis in 12 of these 15 individuals ( -75% of these cases), and one of those in whom allele loss was missed (2087) had a deletion in only 35% of cells karyotyped. The sensitivity with which we are able to detect allele losses in samples from patients without cytogen :tic abnormalities should be comparable to that which we observed in the patients with such abnormalities.
No. of Patients
There were two patients with cytogenetic deletions in at least 50% of karyotyped cells, but loss of heterozygosity was not observed at an informative locus within the apparently deleted region. Patient 291 had a de1(5)(q13q35) in 90% of the cells karyotyped, but the cells remained heterozygous at the D5S70 locus (5q23-31). Leukemia cells from patient 299 had a de1(5)(q13q34), but retained heterozygosity at the D5S71 locus (5q15-21); 52% of the cells karyotyped had this deletion. The karyotypes in these patients were complex with several interchromosomal rearrangements. In one patient (2090), apparently monosomic for chromosome 5, loss of heterozygosity was detected at D5S22, whereas the leukemia cells were heterozygous at D5S39 and D5S78. The leukemia cells from this patient carried a complex rcarrangement involving the remaining chromosome 5. This derivative chromosome had an interstitial deletion of bands q13-31. In addition, this chromosome was involved in an unbalanced translocation with chromosome 17, resulting in loss of 5q35-qter. There were several other rearrangements present, including a del(7)(ql lq34), within which loss of heterozygosity was detected.
It is most likely in these cases with complex karyotypes that, when heterozygosity was observed within an apparently deleted region, it reflected the translocation to another chromosome of a small fragment including an allele of the heterozygous locus.
There are rcports of involvement of B lymphocytes in myeloid leukemias, as evidenced by the presence of immunoglobulin gene rearrangements in leukemic cell^.^' To validate the use of lymphoblastoid cells as controls in this study, we asked whether immunoglobulin rearrangements were present in leukemia cells from a sample of our patients, using a heavy-chain J-region probe (JH) on Southem blots of DNA digested with Hind111 and with Hind111 and BumHI. A rearrangement was detected in one of 20 patients (seven with t-MDS/t-AML and 13 with primary MDS/AML de novo of various subtypes) (Eaton SB, Rios RB, Farber RA, unpublished data); this proportion is similar to those reported in other studies of AML patients.-The one patient with a rearrangement (3050) had AML-MI. As indicated in Table 4 , the leukemia cells from this patient were monosomic for chromosome 7, but the lymphoblastoid cells were heterozygous for RFLP markers on this chromosome. Therefore, although the leukemia may have arisen from a multipotential progenitor cell in this case, the lymphoblastoid line appears to have been derived from B-cell clones that were not involved in the leukemia. These findings indicate that possible lineage infidelity is unlikely to have obscured our ability to detect loss of heterozygosity in more than a small fraction of patients.
DISCUSSION
These results show that loss of heterozygosity at loci on the long arms of chromosomes 5 and 7 in MDS/AML patients who lack cytogenetically detectable deletions is not common. This conclusion is supported by the work of Kere et a1,47 who found no loss of heterozygosity for loci on chromosome 7 (between 7cen and 7q22) in six informative primary MDS/AML de novo patients without abnormalities of this chromosome.
Chromosome loss and reduplication can be ruled out as a mechanism for expression of mutations in tumor-suppressor genes in all cases where heterozygosity was retained; in those cases where markers distal to the critical region were informative, single reciprocal somatic recombination events are also ruled out. Other possible mechanisms for expression of a recessive mutation, including small deletions, gene conversion, or inactivation of an allele by methylation, are not likely to have been detected with the available markers.
A question of particular interest is whether patients with cytogenetically detectable abnormalities of either chromosome 5 or 7, but not both, have evidence of loss of heterozygosity from the other chromosome by mechanisms besides major deletion or monosomy. The number of patients with visible abnormalities of both chromosomes is considerably higher than would be predicted by the numbers of patients with deletions of either chromosome alone, if the two events are independent. This observation suggests the possibility that lesions of both chromosomes might be necessary for development of leukemia. The fact that we never found allele loss from chromosome 5 in individuals with abnormalities of 7 or vice versa implies either that this is not the case or that the mutations involving a tumorsuppressor gene on these chromosomes are more subtle. Alteration of genes on each of these chromosomes may For personal use only. on . by guest www.bloodjournal.org From represent steps in alternative pathways in the progression of the leukemia; alterations in both pathways might then enhance the process. The observation that a high proportion of t-MDS/t-AML patients have loss or deletions of chromosomes 5 and/or 7 indicates that genes on the long arms of these chromosomes are probably involved in the development of the leukemia. Loss of at least one normal copy of one of these genes may be a critical step. When homozygosity, as well as hemizygosity, of a specific chromosomal region is found for a particular type of cancer, the existence of a recessive mutation in a tumor-suppressor gene is suggested. In AML, loss of one allele without a mutation in the remaining gene (ie, a change in gene dosage) may be sufficient to complete this step in the malignant process, which could explain why deletions are so common.
Alternatively, mitotic recombination may simply occur with a much lower frequency in myeloid cells than in some other cell types, and monosomy may be relatively stable in myeloid cells, such that duplication of the remaining homologue would be observed rarely, if at all. If these conditions exist, recessive mutations may be important in these disorders, but hemizygosity may be observed in the critical chromosomal regions much more often than homozygosity, as a reflection of the mechanisms giving rise to expression of mutations.
Much additional work will be needed before we understand the genetic basis of these disorders. More loci within For personal use only. on . by guest www.bloodjournal.org From the critical regions of chromosomes 5 and 7 will be examined to determine whether small deletions have been missed in any of the patients who did not have visible abnormalities; the discovery of such deletions would obviously be a very useful step toward the identification of genes important in AML. There is a striking cluster of cloned growth factor genes in the critical region of 5q4'; these loci will be important markers for further studies, although very few polymorphic sites have been identified in them by screening with restriction enzymes. Work is in progress to saturate the cytogenetically defined critical region of chromosome 5 with polymorphic markers and to construct a high-resolution genetic and physical map of this region.
